Edgewise Therapeutics, Inc.
EWTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. The company carries a $4.68B market cap, placing it firmly in the mid-cap category. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Market Cap
$4.68B
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
-23.72
EPS (TTM)
$-1.85
EPS (Fwd)
$-1.82
ROE
-38.0%
ROA
-25.0%
Cash
$460.7M
Total Debt
$3.6M
Free CF
-$92.3M
52W Change
192.0%
Annual Financials
Cash vs Debt
Where EWTX stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, EWTX finished 26.60% above its 150-day moving average ($34.92) and 37.85% above its 200-day moving average ($32.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EWTX overbought or oversold?
At the August 26, 2026 close, EWTX's RSI(14) was 46.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $460.7M in cash and $3.6M in debt, EWTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$92.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -38.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Edgewise Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EWTX.